Harm Reduction Journal, 2021 Background Some people do not benefit from oral administration of opioid agonist treatment, and an intravenous (IV) formulation may be more suitable. Our objective was to evaluate the willingness of people who regularly inject sublingual buprenorphine to
Salim Mezaache +6 more
doaj +1 more source
The challenge of perioperative pain management in opioid-tolerant patients [PDF]
, 2017 The increasing number of opioid users among chronic pain patients, and opioid abusers among the general population, makes perioperative pain management challenging for health care professionals.
Bifulco, F +9 more
core +6 more sources
Adapting low-dose buprenorphine induction to meet patient needs: A pilot study
Drug and Alcohol Dependence Reports, 2022 Introduction: Low-dose buprenorphine induction (LDBI) has been proposed to initiate buprenorphine in patients who are taking full opioid agonists in order to limit the risk of precipitated withdrawal.
Zoe A. Karavolis, Payel J. Roy
doaj +1 more source
Neuropsychopharmacology Reports, 2020 Aims The United States of America is currently in an opioid epidemic. Heroin remains the most lethal opioid option with its death rate increasing by over 500% in the last decade.
Dominic P. Isaacs +5 more
doaj +1 more source
Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats [PDF]
, 2017 The aim of this study was to describe the joint pharmacokinetic-pharmacodynamic model and evaluate thermal antinociception of a high-concentration formulation of buprenorphine (Simbadol™) in ...
Doodnaught, G M +6 more
core +1 more source
Community pharmacy attitudes and behaviors following a buprenorphine best practices dissemination [PDF]
Mental Health ClinicianIntroduction: Opioid overdose deaths continue to rise despite available safe and efficacious treatments for opioid use disorder, such as buprenorphine. Whereas provider-level access to buprenorphine has improved, community pharmacy-level barriers remain,
Winter Roth, PharmD, BCPP +1 more
doaj +1 more source
Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine‐maintained heroin users [PDF]
Addiction Biology, 2014 AbstractIn spite of the clinical utility of buprenorphine, parenteral abuse of this medication has been reported in several laboratory investigations and in the real world. Studies have demonstrated lower abuse liability of the buprenorphine/naloxone combination relative to buprenorphine alone.
Verena E. Metz +6 more
openaire +2 more sources
Treating Homeless Opioid Dependent Patients with Buprenorphine in an Office-Based Setting [PDF]
, 2007 CONTEXT Although office-based opioid treatment with buprenorphine (OBOT-B) has been successfully implemented in primary care settings in the US, its use has not been reported in homeless patients.
Alford, Daniel P. +6 more
core +3 more sources
Assessment of immunotoxicity of buprenorphine [PDF]
Laboratory Animals, 1994 In order to use buprenorphine as an analgesic in immunological experiments, we have studied the potential immunotoxicity of buprenorphine. Three-week-old male Wistar Riv: TOX rats were subcutaneously treated with buprenorphine by injection of 0.1, 0.4, or 1.6 mg/kg body weight per day over a period of 4 weeks. Concentrations used were within the range
van Loveren, H +4 more
openaire +3 more sources
Buprenorphine for Opioid Use Disorder in the Emergency Department: A Retrospective Chart Review
Western Journal of Emergency Medicine, 2020 Introduction: Emergency care providers routinely treat patients with acute presentations and sequelae of opioid use disorder. An emergency physician and pharmacist implemented a protocol using buprenorphine for the treatment of patients with opioid ...
Kathy T. LeSaint +3 more
doaj +1 more source